SAN RAFAEL, Calif.,
July 9, 2019 /PRNewswire/ -- BioMarin
Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing
therapies for rare genetic diseases, today announced the
appointment of pharmaceutical veteran and former Johnson &
Johnson executive, Liz McKee
Anderson, to its Board of Directors effective July 15th, 2019. Ms. Anderson
serves on the boards of a number of life sciences companies.
Before retiring, Ms. Anderson spent 11 years in executive roles of
increasing responsibility at Johnson & Johnson.
"We are thrilled to have Liz join BioMarin's Board of
Directors. She brings additional expertise in commercial
operations and marketing in the biopharmaceutical industry to an
already outstanding board," said Jean-Jacques Bienaimé, Chairman
and Chief Executive Officer at BioMarin. "Liz's commercial
experience in launching first-in-class and best-in-class therapies,
as well as in developing product portfolio strategy is well suited
to support BioMarin's growth, as we prepare for two potential
product launches of therapies to treat patients with rare genetic
diseases."
"It is an honor to serve on the board of BioMarin, a company
rooted in understanding patients with rare disease and in
developing therapies that make a meaningful difference in their
lives," said Ms. Anderson. "I am looking forward to working
with BioMarin during a time of extraordinary growth not only in its
current portfolio supporting rare disease patients, but also with
an exciting pipeline that has the potential to change the course of
disease."
About Ms. Anderson
Ms. Anderson serves on a number of boards, including
biotechnology companies REVOLUTION Medicines Inc., Bavarian Nordic
A/S, Insmed, Inc., ARO Biotherapeutics Company, and Context
Therapeutics. In addition, she serves on the board of
Huntsworth PLC, an international healthcare and communications
group. Ms. Anderson also serves on the Board of Trustees for
The Wistar Institute, a nonprofit, biomedical research
organization.
Previously, Ms. Anderson served in marketing and operations
roles with increasing levels of responsibility at Johnson &
Johnson culminating in her role as the Worldwide Vice President,
Infectious Diseases and Vaccines at Janssen where she directed the
commercial development of an extensive portfolio of antivirals and
vaccines with responsibility for global marketing, access and
analytics. While at Johnson & Johnson, she held a number
of senior leadership roles in Immunology and Oncology and served on
the Pharmaceuticals Group R&D Development Management Committee
and operating company management boards. Prior to Johnson
& Johnson, Ms. Anderson served as the Vice President and
General Manager of Wyeth Lederle Vaccines from 1997 to 2002.
She also previously held executive commercial operating roles at
Rhone Poulenc Rorer and the American National Red Cross.
Ms. Anderson earned a BS in Engineering from Rutgers College and an MBA in Finance from
Loyola University Maryland Sellinger
School of Business and Management.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for people with serious and
life-threatening rare disorders. The company's portfolio consists
of seven commercialized products and multiple clinical and
pre-clinical product candidates.
For additional information, please visit www.BMRN.com.
Information on BioMarin's website is not incorporated by reference
into this press release.
BioMarin® is a registered trademarks of BioMarin Pharmaceutical
Inc.
Contacts:
|
|
|
|
Investors
|
Media
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-appoints-pharmaceutical-veteran-and-former-j--j-executive-liz-mckee-anderson-to-board-of-directors-300881339.html
SOURCE BioMarin Pharmaceutical Inc.